Moss, 3 November 2021

Gentian Diagnostics ASA is pleased to announce that the results from the
multicenter study "Circulating levels of calprotectin, a signature of neutrophil
activation in prediction of severe respiratory failure in COVID-19 patients: a
multicenter, prospective study (CalCov study)" are published in the scientific
journal "Inflammation Research". The study has been conducted in collaboration
with four hospitals in Spain, with the aim to investigate the role of
calprotectin in prediction of disease severity, including need for mechanical
ventilation and Intensive Care Unit (ICU) admission in patients with Coronavirus
disease 2019 (COVID-19).

The study population included 395 patients presented at four Spanish hospitals
of which 57 (14.4%) required invasive mechanical ventilation and 100 (25.3%)
were admitted to an ICU. Calprotectin levels were measured at the admission to
emergency department and were significantly higher in patients who developed
severe respiratory failure (3.73 mg/L vs. 2.63 mg/L